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ABSTRACT
Although monitoring of vascular accesses by physical examination is nearly as sensitive as surveillance measurements
by vascular access pressure when performed by examiners, the
frequency of examinations is limited by time. We developed
intravascular access pressure surveillance as a surrogate to
physical examination. Using real-time data from hemodialysis
machines, we derived intravascular access pressure ratios for
each dialytic procedure. An automated, noninvasive surveillance algorithm that generated a ‘‘warning’’ list of patients at
risk for thrombosis was formulated. We hypothesized that this
algorithm would reduce access thrombosis frequency. We
designed a study comparing thrombosis rates during a baseline

6-month interval to three subsequent 6-month periods of active
surveillance. Referrals for interventions during this 18-month
period were based on persistently abnormal elevated vascular
access pressure ratio tests (VAPRT) >0.55. Thrombosis rates
declined progressively for arteriovenous grafts (AVG) during
the intervention period compared with the baseline period.
Arteriovenous ﬁstula (AVF) thrombosis rates decreased
during postintervention months 13–18 during employment of
the VAPRT. We conclude that use of VAPRT can reduce
thrombosis rates in vascular accesses, and the magnitude of the
effect is larger and more consistent in arteriovenous grafts
(AVGs) than autologous AVFs.

Hemodialysis (HD) vascular access thromboses result
in missed treatments, disrupt patient treatment schedules, and reduce dialysis facility revenues. The value of
clinical screening or detection of asymptomatic hemodynamically signiﬁcant vascular access stenoses was recognized over 15 years ago and anticipated to reduce
vascular access thrombosis rates (1) In addition, the
adoption of the National Kidney Foundation Kidney
Disease Outcomes Quality Initiative-recommended
vascular access surveillance guidelines (2), by dialysis
centers could reduce vascular access thrombosis rates.
Several techniques are used in surveillance. Vascular
access surveillance by ﬂow measurement has not generally reduced access thrombosis rates (3–5), although
ultrasonic stenosis detection has (6). However, duplex
ultrasonography is probably cost prohibitive for largescale use (7–9).
Elevated venous access pressure (VAP) indicates
stenosis in the venous outﬂow limb. (10–12). Previously,
we demonstrated that the vascular access pressure ratio
test (VAPRT) (Vasc-Alert; Vasc-Alert LLC, Chicago,

IL) could be used to detect stenosis in the venous outﬂow
tract of an access. VAPRT utilizes derived static venous
access pressures (VAPs), taken several times during the
dialysis treatment, and simultaneous mean arterial pressure (MAP) measurements to calculate the mean venous
access pressure ratio (VAPR = VAP ⁄ MAP) for each
treatment (13). Calculation of the VAPR ratio compensates for changes in MAP among and within dialytic sessions. The VAPRT analyzes ratios from consecutive
(HD) treatments to determine the presence of a stenosis.
The primary objective of this study was to test the
hypothesis that VAPRT-based referrals to interventional vascular access centers would reduce access thrombosis rates when added to the routine clinical assessment of
vascular access. A secondary objective was to evaluate
whether reductions of delivered dialysis dose from access
recirculation predicted impending thrombosis, because
many centers still use dialysis dose or recirculation as an
access surveillance method (14,15). Lastly, the urea
reduction ratio (URR), a measure of delivered dialysis
dose, may decline as access blood ﬂow declines
below the prescribed blood pump ﬂow rate (QB) (16).
Therefore, serially declining URR with conﬁrmation by
recirculation measurements could detect impending
vascular access thrombosis.
In this study, we evaluated the effect of surveillance
with VAPRT on access thrombosis rates and monitored URRs as a predictor of thrombosis in vascular
accesses.
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Methods

Clinical Setting
This prospective, observational study was carried out
at a single in-center 50-station hemodialysis facility,
afﬁliated with Henry Ford Hospital, Detroit, MI. The
period of data collection, July 2003 to June 2005,
involved 268 patients: 130 female and 138 male with a
mean age of 63.2  15 years and 98% African American. The monthly in-center patient census ranged from
246 to 265 patients. Treatments were stratiﬁed by vascular access type arteriovenous grafts (AVG) and arteriovenous ﬁstula (AVF) at each dialysis. Subjects who
received dialytic therapy through a (HD) catheter were
excluded from analysis during periods of catheter usage.
All patients with an (AVG) or (AVF) were eligible for
vascular access surveillance (VAS) during any given
month, irrespective of time of entry into the study.
Baseline event data were accrued from the ﬁrst 6-month
period (7 ⁄ 2003 through 12 ⁄ 2003) when VAPR values
were collected, but alerts were not provided to the treating staff and were accordingly not used to make referral
decisions for evaluation ⁄ interventions. In the next three
6-month periods, decisions to refer patients were based
on VAPRs, and the effects of VAPRTs on thrombosis
rates were analyzed monthly.
Data Elements
Data used for VAPRT included machine blood ﬂows,
patient hematocrit (Hct) and venous drip chamber pressures (VDPs) collected when the patient blood pressures
were recorded during treatment. URRs were ascertained
monthly on all patients. For analysis of thrombosis
rates, the date of each patient thrombosis event was
recorded.
Procedures
For any venous tubing set, VDP is a function of access
pressure in needle insertion site, needle gauge, MAP, dialyzer blood ﬂow, tubing length, blood viscosity as a function of hematocrit Hct, and the pressure differential
attributable to the vertical distance between the needle
insertion site and the VDP transducer. Coefﬁcients that
normalize these effects speciﬁc to particular needles and
tubing sets at blood pump ﬂows of 200–500 ml ⁄ min and
Hct 15–40% to calculate true VAP were derived as previously described (13). A unique VAP is calculated each
time the BP is measured during a treatment and the
mean VAPR is calculated. The mean treatment VAPR
represents the mean of at least three readings. Notably,
single treatment VAPRT does not interrupt HD
therapy, and the algorithm using predeﬁned data limits
eliminates spurious readings caused by poor needle
placement. VAPRT is empirically derived using trend
analysis of VAPRs and identiﬁes patients with consistently elevated or progressively increasing intra-access
pressures. From previous work, VAPRs >0.55 represented the optimal balance between sensitivity and speciﬁcity for diagnosing vascular access thrombosis (13) in
AVGs, and this value has been independently validated

by Paulson et al. for AVGs (17). To eliminate spurious
effects from poor needle insertion, the algorithm operationally deﬁned an abnormal VAPRT whenever the
average treatment VAPR exceeded 0.55 during three
consecutive HD treatments. Patients were then placed
on a monthly ‘‘Access Warning List’’ prompting further
evaluation and possible intervention. In the absence of
intervention, alerts would continue.
Event Rates
Events per patient-year were calculated from documented treatment events that involved AVFs or AVGs.
Throughout the study period, clinical staff documented
the inability to conduct HD by failure to obtain sufﬁcient blood ﬂow. These events were ‘‘labeled’’ as possible
thrombotic events, with actual thrombosis conﬁrmed by
subsequent physical examination or at endovascular
evaluation.
Clinical Assessments (Monitoring)
Treatment length reductions from access clotting or
missed treatments were recorded with HD duration,
swelling of the extremity ipsilateral to the access, cannulation difﬁculties, and events of prolonged bleeding,
infection or inﬁltration, and aneurysm formation.
Patients who experienced such events were examined for
possible vascular stenosis (Table 1) and vascular access
evaluations were scheduled when clinical suspicion was
high. Lastly, URR values were reviewed monthly to
evaluate trends in dialysis adequacy.
Data Presentation
All patients with an AVF or AVG in the 2-year study
period were included in the analysis. The thrombosis
rate was calculated for each access type in four 6-month
periods as the ratio of the number of thrombotic events
per total person-years of follow-up. Each patient’s
cumulative follow-up for a 6-month period was calculated and summed over patients with the same access

TABLE 1. Vascular access monitoring sheet
Patient name
Recorded by clinical staff
Dialysis duration, not achieved
Extremity swelling
Difﬁcult cannulation
Prolonged bleeding
Decrease in Kt ⁄ V or URR
Unable to achieve adequate blood pump ﬂow
Vascular ‘‘steal’’ symptoms or pain
Signs or symptoms of infection
Signs or symptoms of inﬁltration
Aneurysm formation
Other______
Analyzed by physician ⁄ access coordinator
‘‘Warning List’’ (Increased VAPRT)

Yes

No

O
O
O
O
O
O
O
O
O
O
O
O
O
O

O
O
O
O
O
O
O
O
O
O
O
O
O
O

Data input is conducted during clinical rounds. The last two
items were added in the last three 6-month periods after active surveillance was implemented.
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type. The ﬁrst 6-month period was considered the baseline, and no alerts were generated during this period.
Vascular access surveillance using VAPRT with alerts to
the respective health-care providers was introduced and
continued from months 7 through 24.
Six-month rates were recalculated and included all
individuals receiving dialysis during those periods. To
examine longitudinal differences in thrombosis rates, a
generalized estimating equation (GEE) was used that
produced a negative binomial regression model with
total person-years of follow-up for an interval. This
value represented the value as the offset variable in the
model. This approach modeled the count nature of
the data and adjusted for correlations within the same
individuals over the study duration.
URRs were analyzed by ANOVA for repeated measures. Statistical analysis was performed with SAS v 9.2
(SAS v9.2, Cary, NC), and presented as means  SEM,
with the level of signiﬁcance set at 0.05.
Results
Hemodialysis treatments were analyzed when an
AVG or AVF was utilized for treatment. More than
146,000 data samples for VAPR determinations were
evaluated during this 24-month study in which a total of
91 thrombotic events occurred, 56 in AVGs and 35 in
AVFs (Table 2). On average, during the entire study

TABLE 2. Thrombosis data for each 6-month period are shown

Access Period
Graft

Follow-up Thrombosis
patient
rate per
Patients Clots
years
person-year

Preintervention
(6 months)
Postintervention
(0–6 months)
Postintervention
(7–12 months)
Postintervention
(13–18 months)

115

21

50.9

0.413

138

19

63.3

0.300

116

8

54.5

0.147

99

8

45.5

0.176

Fistula Preintervention
(6 months)
Postintervention
(0–6 months)
Postintervention
(7–12 months)
Postintervention
(13–18 months)

85

56
5

36.5

0.137

104

12

48.3

0.249

93

15

42.6

0.352

75

3

37.2

0.081

35
During the 24-month monitoring study, 56 arteriovenous grafts
and 35 arteriovenous ﬁstulas thrombosed during the 18-month
interval. The baseline vascular access thrombosis rate (thrombosis
rate) was 0.41 events per person-year prior to the completion of
systematic implementation of VAPRT, and declined to 0.18 in the
last post intervention period. In AVG, a persistent and steady
decline of thrombosis rate is evident during 3, successive 6-month
intervals of utilizing the vascular access pressure ratio test (VAPRT). In AVF, the pattern differs and a decrease in thrombosis
rate effect is not seen until the last 6 month period. For AVG and
AVF combined 6-month thrombosis data, the baseline thrombosis
rate of 0.297 events per person-year prior declined to 0.133 at the
completion of VAPRT implementation.
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period, there were 117 patients with AVGs and 89
patients with AVFs. Patients were in the study group for
92% of the total possible time, with the missing 8% due to
a change to a different access, death or loss to follow-up.
The vascular access thrombosis rates are summarized
(Table 2). In AVG, the thrombosis rate declined progressively from a preintervention rate of 0.41 to 0.18
events per person-year, during the ﬁnal postintervention
period (Fig. 1). The AVF thrombosis rate unexpectedly
increased during the ﬁrst year before falling to a lower
event rate of 0.081 events per person-year during postintervention months 13–18 (Fig. 1). Combining both
access types, the rate ⁄ person-year declined consistently
from a preintervention rate of 0.297 events per personyear to 0.13 events per person-year (Table 2 and Fig. 2)
in the last postintervention period. This represents a
57% decrease overall. The number of clotting episodes
within each 6-month period decreased from 26 in the
control period to 11 events in the last.
The AVG relative risk (RR) for thrombosis demonstrated a statistically signiﬁcant decline from months
7 to 12 months, with a minimal decline during months
13 to 18. AVG access had a relative risk for thrombosis
of 0.44 relative to baseline conﬁdence interval (CI:
0.18–1.09), during months 13 to 18 (Table 3). By
contrast, AVFs had a near-signiﬁcant increase in thrombosis rate during postintervention months 7 to 12 compared with baseline. In postintervention months 13 to
18, the rate decreased, relative to baseline (RR 0.61;
CI 0.19–1.92), but this result did not reach statistical
signiﬁcance (Table 3).
During the 24-month study period, we determined
VAPRTs and the number of interventional vascular procedures. Table 4 delineates the decreased number of
alerts from the ﬁrst 6-month control period to the ﬁrst
vascular access surveillance period, which then remained
stable during the last 2, 6-month periods. On average,
the number of total alerts per access decreased from 2.3
(range 0–5) to 1.3 alerts (range 0–3) per 6 month period.
During the active surveillance period (periods 3–4),
attempts were made to obtain referrals done after
the ﬁrst alert was conﬁrmed in the next month. The
fraction of accesses on alert decreased from 38% to
21–23% in the surveillance period. As shown in Fig. 3,
the number of angioplasties per 6-month period tended
to remain constant after vascular access surveillance
was introduced, but the ratio of procedures requiring
thrombectomy ⁄ thrombolysis ⁄ PTA compared with simple PTA declined.
We retrospectively examined changes in URR in the
6-month interval pre-and post-vascular access thrombosis. No signiﬁcant changes occurred in URR during the
6 months before or after AVG thrombosis (Fig. 4). By
contrast, URR decreased signiﬁcantly in AVF by nearly
6% from 73% to 67% in the month preceding thrombosis and then improved only minimally after angioplasty.
The mean nadir values for both access types were still
above the minimum considered ‘‘adequate’’ dialysis.
There was no change in URR in the 2 months before
thrombosis in AVGs, but there was an abrupt onset of
decreased dialysis dose delivery in the month before
thrombosis in AVFs using repeated measures ANOVA
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Fig. 1. Raw thrombosis events by vascular access type. Thrombosis events for arteriovenous grafts (AVGs) and arteriovenous ﬁstulas
(AVFs) are displayed in the baseline period when VAPRT alerts were not provided and during three, consecutive 6-month intervals of
active monitoring. VAPRT was the sole method of vascular access surveillance and was associated with a progressive decline in thrombosis
rates of AVGs. For AVFs, a reduction did not occur until the last interval.

TABLE 3. Thrombosis risk by vascular access type
Comparison
Graft
Interval 2 vs. Interval 1
Interval 3 vs. Interval 1
Interval 4 vs. Interval 1
Fistula
Interval 2 vs. Interval 1
Interval 3 vs. Interval 1
Interval 4 vs. Interval 1

Fig. 2. Thrombosis event rate reduction of vascular accesses
after implementation of VAPRT. The 24-month study was divided
into a 6-month control interval followed by three, 6-month intervals at a single in-center hemodialysis unit with a mean patient census of 227. VAPRT was not utilized during the baseline period.

(Fig. 5). This reduction was evident in AVFs at )30 and
+30 days. *p < 0.05 compared to 60 days. URR
remained depressed by nearly 8.2% during the succeeding several months postthrombosis in patients with
thrombosed AVFs. In some patients, the lower URR
was the results of a greater requirement for dialysis catheter use as salvage with thrombolysis ⁄ PTA was unsuccessful.
Discussion
In this study, systematic use of VAPRT surveillance
technology reduced the thrombosis rate by generating a
simple-to-read ‘‘warning list’’ of patients with possible
access dysfunction. No special equipment or clinical
staff was required by VAPRT because it is an electronically automated process. After 18 months of applica-

RR (95% CI)

p-value

0.74 (0.35, 1.57)
0.37 (0.15, 0.90)
0.44 (0.18, 1.09)

0.439
0.028
0.078

1.78 (0.69, 4.61)
2.55 (0.96, 6.76)
0.61 (0.19, 1.92)

0.237
0.061
0.398

All access relative risk (RR) estimates. The arteriovenous graft
rate demonstrated statistically signiﬁcant decline from months 7
to 12, with a minimal decline during months 13 to 18. A subject
with an AVG access had a RR for thrombosis of 0.44 relative to
baseline conﬁdence interval (CI: 0.18–1.09). In the postintervention
period from (13–18) months, reduction in rate ⁄ patient year was
seen in the 4th 6-month period. The AVF group showed an
increase in thrombosis rate during postintervention months
7–12 month compared with baseline. At postintervention months
(13–18), the rate was decreased, with a RR 0.61 (0.19–1.92) relative
to baseline.

tion, the overall thrombosis rate decreased 57% from
0.29 to 0.13 events per patient-access-year. Concordantly, the number of interventions performed to maintain access patency, and the number of ‘‘emergency’’
procedures was reduced. During the control period, 115
procedures were performed, and 55 of these included a
thrombectomy prior to angioplasty. During the last two
study intervals, thrombectomies in permanent accesses
(both AVG and AVF) decreased by half, while frequency of simple angioplasties did not increase. In fact,
the total number of procedures decreased from 180 at
baseline to 129, 115, 112 in each subsequent period.
However, there was a shift to a greater proportion of
elective PTA as opposed to thrombolysis ⁄ thrombectomy with PTA.The fraction of procedures triggered by a
thrombosis decreased from 31% at baseline to 21% in
the last period. These results are similar to those
reported by Besarab et al. (10) who evaluated static pressure ratios, and McCarley et al. (18) whose study
involved ﬂow-based technology.

ACCESS PRESSURE SURVEILLANCE

TABLE 4. Vascular access warning list summary
Period
1
2
3
4

Total
warnings (N)
386
196
220
223

Alerts per
access in period
2.3
1.3
1.4
1.3






1.2
0.5
0.6
0.6

Monthly percent
alert rate
38.0
21.2
22.7
22.1






3.5
3.0
1.3
2.2

Rates are expressed as number of warnings for all vascular
accesses, arteriovenous grafts, and ﬁstulas combined during the
control and surveillance periods.

The VAPRT surveillance technology can be used to
prioritize patients with the greatest expectation of access
failure. Vascular access warning reports triage patients
with VAPRT’s >0.55 their accompanying individualized trend reports ⁄ graphs of VAPRs and pump blood
ﬂows (Fig. 6) delineate those accesses at risk for clotting.
Monthly reports highlight previous months on the warning list, interventions, clotting incidents with blood
ﬂows, and historical VAPRTs. A nurse practitioner or
physician conducts a careful physical inspection of
vascular accesses for patients who are ‘‘on alert,’’ and
completes a patient-speciﬁc Access Information Sheet
(Table 1) prior to referral for intervention.
An impact of the warning list on the AVG thrombosis
rate was evident within the ﬁrst 6-month period of systematic use. Graft thrombosis rate progressively
decreased during the three designated interventional
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periods with the rate stabilizing in the last two periods.
The gradual rather than the anticipated stepwise functional decrement may reﬂect the transition period for
training staff and referring patients for vascular access
evaluation intervention. Impediments to further ratelowering include patient refusal to undergo access evaluation and a small proportion of vascular accesses that
have previously and repeatedly failed interventions.
Most individuals do not develop an access thrombosis
within a month of the appearance of their vascular
access on the ‘‘warning’’ list. The persistence of a high
proportion of alerts in the ﬁrst 6 month control period
reﬂects cumulative time on this list of the same accesses
until corrective actions were taken. In the absence of
referral and therefore endoluminal ⁄ surgical intervention, there is no reason for the alert rate to fall. Only successful detection and intervention on stenosis should
reduce the alert rate by correcting the stenosis that lead
to the initial alert leading to its subsequent absence in the
months thereafter. Implementation of VAPRT process
did exactly that. It lowered the total number of monthly
alerts, reducing the fraction of accesses on alert from
38% in the control period to 21–22% in the three subsequent active surveillance periods.
Static access pressures are generally lower in AVFs
compared to AVGs (12,19,20), especially in forearm
ﬁstulas. The common occurrence of inﬂow segment stenosis further lowers the pressures within the access
(19,20). This differs from AVGs where stenosis is

Fig. 3. Vascular access interventions decrease after VAPRT implementation. The 24-month study was divided into a 6-month baseline
interval followed by three, 6-month consecutive intervals at a single in-center hemodialysis unit with a mean patient census of 227. VAPRT
was used for vascular access surveillance during the 18 months following the baseline interval. Absolute numbers of vascular access
interventions, represented as angioplasties (‘‘left panel’’) or thrombectomies (‘‘right panel’’), declined from respective control periods at all
follow-up intervals.
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Fig. 4. Time-varying urea reduction rates (URRs) during the vascular perithrombosis period. Mean URRs are only altered during the
progression of thrombosis of arteriovenous ﬁstulas (AVFs), compared with arteriovenous grafts (AVGs). The reduction of URRs in AVFs
is evident within 30 days of ﬁstula thrombosis and within 30 days of having achieved stability (Day 60). After development of thromboses,
AVF URRs remained lower, necessitating hemodialysis catheter placement in patients with AVFs (n = 6) and patients with AVGs
(n = 13).

Fig. 5. Time-varying urea reduction ratios (URRs) in thrombosed vascular accesses. Time = 0 is deﬁned as the day of vascular
access thrombosis. URRs declined in arteriovenous ﬁstulas (AVFs)
but not in arteriovenous grafts (AVGs). This reduction was evident
in AVFs at )30 and +30 days. *p < 0.05 compared to )60 days.
p < 0.05 compared between grafts and ﬁstulas (repeated measures,
two-way analysis of variance).

typically in the outlet or mid-portion (21) elevating the
pressures. Thus, the probability of achieving the critical
value for VAPR of 0.55 is higher in AVG than AVF.
This difference in hemodynamics alone may have
resulted in the obvious difference in thrombotic event
rates between AVG and AVF. The data clearly show
that reduction in vascular access thrombosis occurred
promptly in AVG but only after a protracted period of
more than 12 months in AVF. This was initially puzzling and several possible explanations were looked for.
Like most programs, we attempted to construct more
wrist AVF during the initial stages of the Fistula First
Initiative (note the increases in AVF years at risk in

periods 2 and 3 compared to 1 and 4, Table 2). At the
beginning of the baseline period, 41.3% of 179 accesses
were AVF. The total number of AVFs increased during
the baseline period and 42.5% of all permanent accesses
used at any point in the period were AVF (Table 2). During the 18-month intervention period, 54% of 92 ‘‘new’’
permanent accesses were AVF, up from the 42.5% in
the baseline period. Of the 31 new AVFs used in period 1
and 2, 22 were constructed by our surgeon; 19 were forearm AVFs. In the last period, he constructed 11 of 15
new AVF, 8 were at the elbow level. The surgical records
for the other patients are external to the health system.
The initial increase in thrombosis rate may have
resulted from attempts to salvage inadequately functioning, nonmature AVF in which the most common lesion
is an inﬂow stenosis PTA balloon pressures required for
successful lasting dilatation are larger in such AVF than
in AVG, but our interventionist did not exceed 15 atm
of pressure during these periods. It is also known that
the PTA procedure itself may injure the vessels and
predispose it to thrombosis if there is inadequate longlasting correction of the stenosis. The lack of efﬁcacy
may explain the inability to decrease thrombosis rate
initially. The absence of improvement in URR, which
remained depressed even after interventional procedures
(see Figs. 4 and 5), suggests inadequate correction of the
underlying stenosis.
Subsequently, the emphasis of Fistula First Initiative
led to the construction of more elbow-level ﬁstulas,
many of which are prone to the development of stenoses
at both the inﬂow and outlet of the access. Elbow level
accesses are subject to outlet stenosis at the ‘‘cephalic
arch’’ if cephalic vein and the outﬂow ‘‘swing segment’’
if basilic. Stenosis in these downstream segments elevates
intra-access pressure, and the pressure proﬁle begins to
mimic that of AVGs permitting earlier detection of these
lesions in the outﬂow. In addition, we began to trend
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Fig. 6. Time-varying vascular access pressure ratios (‘‘lower plot, VAPRs’’) and vascular access blood ﬂows (‘‘upper plot, Qb’’) from a
single patient AVG. Surgical intervention dates correspond with increasing VAPR, deﬁned as the vascular access pressure measured at the
venous limb of a vascular access divided by mean arterial pressure, derived from hemodialysis machine blood pressure measurements.

delivered blood pump ﬂow along with the VAPR to
detect inﬂow lesions (Fig. 6). Our subsequent experience
is that combining the two parameters permits detection
of AVF stenoses wherever their location is. Once all the
elements were in place, we were able to demonstrate a
reduction in thrombosis rate below basal in the last 6month period although the previous upward variations
in periods 2 and 3 precluded demonstration of a statistically signiﬁcant effect. With the small absolute number
of ﬁve thromboses in the basal period, it would require a
much larger study in AVF to demonstrate that the 40%
reduction to three thrombotic events in the ﬁnal period
was clinically important.
Thrombosis rates for both access types from 2006–
2008 have remained at the levels seen during the last
6-month period (G. Zasuwa, S. Frinak, A. Besarab, and
J. Yee, unpublished data). The rate of formation of
stenosis is not inﬂuenced by our surveillance technique.
There are limitations to this study. The ﬁrst is the
absence of a control group where only physical or clinical evaluations would have been performed for the entire
2 year duration of the study and event rates tabulated.
Vascular access examination is important and capable
of delineating access dysfunction (22–24), and it has been
touted as equivalent to static intra-access pressure measurement (25). In AVGs, the positive predictive value by
physical examination or clinical clues for stenosis varies
from 69–70% (26,27) to 98% (28). A mean positive predictive value of 75% can be calculated form available
data. As recently reported, accuracy is highest for detecting stenosis within the AVG, followed by the outlet, and
least for the inﬂow (sensitivity of only 33%) (29).
Similarly physical examination of AVF despite its high
speciﬁcity of 90% in detecting access dysfunction has a
highly variable sensitivity varying greatly from 38% to
96% (30). Achievement of superior accuracy requires

uncommon expertise and multiple examinations by
properly trained, skilled, and experienced individuals,
both uncommon circumstances in USA dialysis centers
today. We felt that having such a control group for
the entire 2 year period would have been a violation of
clinical responsibility.
Sequential monthly URR values even if performed
for months in advance of thrombosis were not predictive
of developing stenosis in grafts and therefore of impending access thrombosis. We noted that the mean nadir
URR values for both access types was still above the
minimum URR value of 65% indicative of ‘‘adequate’’
dialysis. Development of recirculation producing a
signiﬁcant decrease in URR requires that access ﬂow
be much less than prescribed blood pump ﬂow, which
averaged 450 ml ⁄ min for AVGs and 420 ml ⁄ min for
AVFs (31). Most AVG will thrombose at access ﬂows
<500 ml ⁄ min (2). The test is therefore useless in AVG.
As access ﬂow in grafts is almost never limiting for
URR, it is not surprising that it did not change after
intervention. By contrast, up to one-third of dysfunctional AVFs will show access recirculation (32) that may
be subclinically manifested as a decrease in urea reduction ratio (URR) or Kt ⁄ V (but not always to frankly
inadequate levels). Recirculation could proceed for
months as AVF patency can be maintained at blood
ﬂows <500 ml ⁄ min. Our data contend that for AVF,
decreases in URR or KT ⁄ V from their respective baselines are present for just 1–2 months before thrombosis.
Therefore, in AVFs, a sudden decrease in URR from
baseline, even when the URR remains above a minimally acceptable value, warrants more urgent evaluation. However, the lead time is short and the stenosis
usually so advanced that many AVF, particularly wrist
level, cannot be salvaged or improved sufﬁciently. As a
result, lower URRs tend to persist after intervention.
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Our center has used ultrasonic dilution blood ﬂow
techniques to detect stenosis (33–35). We abandoned this
methodology because it required dedicated staff, accuracy was operator-dependent, and the time requirement
made it impractical for use in our dialysis units. However, the utility of access ﬂow measurements when performed according to the Kidney Disease Outcome
Quality Initiative was clearly documented by Wijnen
et al. (35). Thrombectomy procedures were reduced by
over 60%, whereas the number of radiological interventions more than doubled, from 0.33 to 0.88 events ⁄
patient-year, following addition of ﬂow surveillance
to ‘‘routine’’ clinical monitoring. Access survival was
unaffected.
Randomized clinical trials (RCT) have failed to show
that surveillance improved access survival. In RCTs, the
addition of a surveillance technique (pressures or ﬂow)
was compared with an established regimen of monitoring by physical examination and clinical manifestations
of dysfunction. As previously discussed, physical examination is an effective technique when carried out by
experienced staff. By contrast, most observational studies were carried out in centers where monitoring was
ineffective. In our study, we did not attempt to certify or
attest to the ‘‘quality’’ of the monitoring conducted by
the clinical staff. Nevertheless, our results obtained in
the course of a busy, real-world practice; demonstrate
access thrombosis rate reductions are possible in such
settings, particularly in AVG, by adding our surveillance method. We do encourage future, sufﬁciently
powered, double blinded, and randomized study of vascular access surveillance methods effects on meaningful
outcomes such as thrombosis rate, useful access lifespan till abandonment, or economic costs. Such studies
may need to be much larger than those previously
performed and involve multi-center cooperation. The
sample size for two recent Dialysis Access Consortium
studies to demonstrate a 25% difference in event rates
between drug and no-drug required 1000 subjects
(36,37).
In conclusion, we document that the access thrombosis rate can be reduced by access surveillance using the
VAPRT algorithm to detect temporal changes in derived
static pressure ratios for AVFs and AVGs. The effect is
most consistent in grafts and inﬂuenced by the type of
AVF. We also demonstrate that alterations of URR
inadequately predict impending vascular access thrombosis, particularly in grafts. The latter should be abandoned as a surveillance technique. Use of the
surveillance technique seems to produce a shift from
PTA usage for salvage of thrombosed graft to more elective PTA of stenosis in patent grafts, suggesting perhaps
‘‘more effective’’ selection of accesses for intervention.
In grafts, more than 60% of accesses may have stenosis,
but only some of these will produce clinical dysfunction.
Clinical monitoring alone may result in referrals wherein
many unnecessary PTA’s are performed. We believe that
the VAPRT surveillance methodology may more
selectively identify those stenoses producing operative
dysfunction, which if left unattended eventuate in
thrombosis. Additional studies would be needed to conﬁrm this.
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